Sunho Biologics (02898) Releases February 2026 Monthly Return
Bulletin Express
Mar 02
Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.
The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.